Last reviewed · How we verify
Mencevax™ACWY
Mencevax ACWY is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroups A, C, W, and Y.
Mencevax ACWY is a meningococcal conjugate vaccine that stimulates the immune system to produce antibodies against Neisseria meningitidis serogroups A, C, W, and Y. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
At a glance
| Generic name | Mencevax™ACWY |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Meningococcal conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains polysaccharide capsular antigens from meningococcal serogroups A, C, W, and Y conjugated to a protein carrier (tetanus toxoid), which enhances immunogenicity and T-cell dependent immune responses. Upon administration, it primes both humoral and cellular immunity to recognize and neutralize these meningococcal strains, providing protection against invasive meningococcal disease caused by these serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
- Fever
Key clinical trials
- Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects (PHASE3)
- Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects (PHASE2)
- Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds (PHASE3)
- Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults (PHASE3)
- Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine (PHASE2)
- Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects (PHASE3)
- Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old (PHASE2)
- Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |